Emmanuela E Ambrose1, Julie Makani2, Neema Chami1, Tulla Masoza1, Rogatus Kabyemera1, Robert N Peck3,4, Erasmus Kamugisha5, Alphaxard Manjurano6, Neema Kayange1, Luke R Smart3,4. 1. Department of Paediatrics and Child Health, Catholic University of Health & Allied Sciences and Bugando Medical Centre, Mwanza, Tanzania. 2. Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. 3. Department of Internal Medicine, Catholic University of Health & Allied Sciences and Bugando Medical Centre, Mwanza, Tanzania. 4. Center for Global Health, Weill Cornell Medicine, New York, New York, USA. 5. Department of Biochemistry and Molecular Biology, Catholic University of Health & Allied Sciences, Mwanza, Tanzania. 6. National Institute for Medical Research, Mwanza Research Centre, Mwanza, Tanzania.
Abstract
BACKGROUND: Worldwide, hemoglobinopathies affect millions of children. Identification of hemoglobin disorders in most sub-Saharan African countries is delayed until clinical signs of the disease are present. Limited studies have been conducted to understand their prevalence and clinical presentation among newborns in resource-limited settings. METHODOLOGY: This was a prospective cohort study. Newborns (aged 0-7 days) at two hospitals in Northwestern Tanzania were enrolled and followed prospectively for 6 months. Clinical and laboratory information were collected at baseline. Participants were screened for hemoglobinopathies using high-performance liquid chromatography. Clinical and laboratory follow-up was performed at 3 and 6 months for those with hemoglobinopathies as well as a comparison group of participants without hemoglobinopathies. RESULTS: A total of 919 newborns were enrolled. Among these, 1.4% (13/919) had sickle cell anemia or Hb S/β0 -thalassemia (Hb FS), and 19.7% (181/919) had sickle cell trait or Hb S/β+ thalassemia (Hb FAS). Furthermore, 0.2% (two of 919) had β+ -thalassemia. Red cell indices compared between Hb FS, Hb FAS, and Hb FA were similar at baseline, but hemoglobin was lower and red cell distribution width was higher in children with Hb FS at 3- and 6-month follow-up. Febrile episodes were more common for children with Hb FS at 3- and 6-month follow-up. CONCLUSION: The prevalence of sickle cell disease among neonates born in Northwestern Tanzania is one of the highest in the world. Newborn screening is needed early in life to identify neonates with hemoglobinopathies so that clinical management may commence and morbidity and mortality related to hemoglobinopathies be reduced.
BACKGROUND: Worldwide, hemoglobinopathies affect millions of children. Identification of hemoglobin disorders in most sub-Saharan African countries is delayed until clinical signs of the disease are present. Limited studies have been conducted to understand their prevalence and clinical presentation among newborns in resource-limited settings. METHODOLOGY: This was a prospective cohort study. Newborns (aged 0-7 days) at two hospitals in Northwestern Tanzania were enrolled and followed prospectively for 6 months. Clinical and laboratory information were collected at baseline. Participants were screened for hemoglobinopathies using high-performance liquid chromatography. Clinical and laboratory follow-up was performed at 3 and 6 months for those with hemoglobinopathies as well as a comparison group of participants without hemoglobinopathies. RESULTS: A total of 919 newborns were enrolled. Among these, 1.4% (13/919) had sickle cell anemia or Hb S/β0 -thalassemia (Hb FS), and 19.7% (181/919) had sickle cell trait or Hb S/β+ thalassemia (Hb FAS). Furthermore, 0.2% (two of 919) had β+ -thalassemia. Red cell indices compared between Hb FS, Hb FAS, and Hb FA were similar at baseline, but hemoglobin was lower and red cell distribution width was higher in children with Hb FS at 3- and 6-month follow-up. Febrile episodes were more common for children with Hb FS at 3- and 6-month follow-up. CONCLUSION: The prevalence of sickle cell disease among neonates born in Northwestern Tanzania is one of the highest in the world. Newborn screening is needed early in life to identify neonates with hemoglobinopathies so that clinical management may commence and morbidity and mortality related to hemoglobinopathies be reduced.
Authors: Julie Makani; Albert N Komba; Sharon E Cox; Julie Oruo; Khadija Mwamtemi; Jesse Kitundu; Pius Magesa; Stella Rwezaula; Elineema Meda; Josephine Mgaya; Kisali Pallangyo; Emelda Okiro; David Muturi; Charles R Newton; Gregory Fegan; Kevin Marsh; Thomas N Williams Journal: Blood Date: 2009-11-09 Impact factor: 22.113
Authors: F M Gill; L A Sleeper; S J Weiner; A K Brown; R Bellevue; R Grover; C H Pegelow; E Vichinsky Journal: Blood Date: 1995-07-15 Impact factor: 22.113
Authors: Grace Ndeezi; Charles Kiyaga; Arielle G Hernandez; Deogratias Munube; Thad A Howard; Isaac Ssewanyana; Jesca Nsungwa; Sarah Kiguli; Christopher M Ndugwa; Russell E Ware; Jane R Aceng Journal: Lancet Glob Health Date: 2016-01-29 Impact factor: 26.763
Authors: Frédéric B Piel; Thomas V Adamkiewicz; Djesika Amendah; Thomas N Williams; Sunetra Gupta; Scott D Grosse Journal: Genet Med Date: 2015-12-03 Impact factor: 8.822
Authors: Frédéric B Piel; Anand P Patil; Rosalind E Howes; Oscar A Nyangiri; Peter W Gething; Mewahyu Dewi; William H Temperley; Thomas N Williams; David J Weatherall; Simon I Hay Journal: Lancet Date: 2012-10-25 Impact factor: 79.321
Authors: Léon Tshilolo; George Tomlinson; Thomas N Williams; Brígida Santos; Peter Olupot-Olupot; Adam Lane; Banu Aygun; Susan E Stuber; Teresa S Latham; Patrick T McGann; Russell E Ware Journal: N Engl J Med Date: 2018-12-01 Impact factor: 91.245
Authors: Siana Nkya; Lillian Mtei; Deogratias Soka; Vera Mdai; Promise B Mwakale; Paul Mrosso; Issa Mchoropa; Stella Rwezaula; Mary Azayo; Nzovu Ulenga; Melkiory Ngido; Sharon E Cox; Brenda S D'Mello; Honorati Masanja; Gregory S Kabadi; Frederick Mbuya; Bruno Mmbando; Yvonne Daniel; Allison Streetly; Japhet Killewo; Furahini Tluway; Magdalena Lyimo; Julie Makani Journal: Int Health Date: 2019-11-13 Impact factor: 2.473
Authors: Neema Chami; Duncan K Hau; Tulla S Masoza; Luke R Smart; Neema M Kayange; Adolfine Hokororo; Emmanuela E Ambrose; Peter P Moschovis; Matthew O Wiens; Robert N Peck Journal: PLoS One Date: 2019-06-20 Impact factor: 3.752
Authors: Belinda Kweka; Eric Lyimo; Kidola Jeremiah; Suzanne Filteau; Andrea M Rehman; Henrik Friis; Alphaxard Manjurano; Daniel Faurholt-Jepsen; Rikke Krogh-Madsen; George PrayGod; Douglas C Heimburger Journal: PLoS One Date: 2020-12-31 Impact factor: 3.240
Authors: Emmanuela E Ambrose; Luke R Smart; Mwesige Charles; Arielle G Hernandez; Teresa Latham; Adolfine Hokororo; Medard Beyanga; Thad A Howard; Erasmus Kamugisha; Kathryn E McElhinney; Erius Tebuka; Russell E Ware Journal: Bull World Health Organ Date: 2020-09-28 Impact factor: 13.831